KOMZIFTI (Ziftomenib) Capsules

KOMZIFTI (ziftomenib), from Kura Oncology and Kyowa Kirin, is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options — the first and only once-daily targeted therapy for this patient population.

Ziftomenib is a menin inhibitor. It blocks the interaction between menin and the KMT2A protein complex, disrupting a key oncogenic signaling pathway that drives leukemic cell growth in NPM1-mutated AML, helping to stop the growth and spread of leukemia cells.

• Differentiation syndrome, a potentially life-threatening condition, has been reported with menin inhibitors and requires prompt recognition and management.
• QT interval prolongation is a class consideration; ECG monitoring may be required.
• KOMZIFTI should not be started until the white blood cell (WBC) count is reduced to less than 25 x 10&sup9;/L.
• Must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
• Common side effects reported in clinical trials include cytopenias and infections.

What documents are required to import KOMZIFTI to India?

KOMZIFTI may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered hemato-oncologist
• Molecular test report confirming NPM1-mutated relapsed/refractory AML
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is KOMZIFTI available in India?

KOMZIFTI is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source KOMZIFTI from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For KOMZIFTI cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — November 13, 2025.

What is KOMZIFTI used for?

KOMZIFTI treats relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation in adults with no satisfactory alternative treatment.

Who manufactures KOMZIFTI?

KOMZIFTI is developed by Kura Oncology and Kyowa Kirin.

What is the dosage of KOMZIFTI?

600 mg taken orally once daily, on an empty stomach, until disease progression or unacceptable toxicity.

How much does KOMZIFTI cost in India?

Cost depends on monthly quantity and sourcing logistics — share your prescription with IPN for a quote.